MML Investors Services
NKTR icon

MML Investors Services’s Nektar Therapeutics NKTR Stock Holding History

MML Investors Services’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-186
Closed -$296K – 1399
2018
Q1 		$296K Buy
+186
New +$240K 0.01% 1086

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MML Investors Services's NKTR Position: Q2 2018 in Review

MML Investors Services sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 186 shares — an estimated $296K sold.

MML Investors Services first reported a position in NKTR in Q1 2018 and held it in 1 quarter. The position peaked at $296K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • MML Investors Services reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • MML Investors Services sold 186 Nektar Therapeutics shares in Q2 2018, an estimated $296K.
  • MML Investors Services first reported a position in Nektar Therapeutics in Q1 2018 and held it in 1 quarter.
  • MML Investors Services's Nektar Therapeutics position peaked at $296K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on MML Investors Services's 13F filing for Q2 2018, filed 13 Aug 2018.